The comparative effects of tacrolimus and hydrocortisone in adult atopic dermatitis: an immunohistochemical study

• DOI: 10.1111/j.1365-2133.2006.07609.x
• Publication Date: 2006-11-28T13:10:12Z
• Authors: M. Caproni; D. Torchia; E. Antiga; M. Terranova; W. Volpi; E. Del Bianco; A. D'Agata; P. Fabbri
• Keywords: Adult; Male; Hydrocortisone; Administration, Topical; Antibodies, Monoclonal; Middle Aged; Immunohistochemistry; Tacrolimus; Dermatitis, Atopic; 3. Good health; Ointments; 03 medical and health sciences; Treatment Outcome; 0302 clinical medicine; Cytokines; Humans; Female; Receptors, Cytokine; Immunosuppressive Agents; Atopic dermatitis; Aged

While many studies have demonstrated the efficacy and safety of tacrolimus ointment in the treatment of atopic dermatitis (AD), only a few have investigated the effects of tacrolimus on inflammatory cells and their cytokine gene expression in patients with AD.To characterize further the immunophenotype of infiltrating cells and the production of certain cytokines before and after treatment with topical tacrolimus and hydrocortisone butyrate.Nine adult patients with moderate to severe AD were treated with tacrolimus ointment, while seven control patients were treated with hydrocortisone butyrate ointment. We performed lesional skin biopsies before and after treatment. These were stained immunohistochemically with a panel of monoclonal antibodies including those to CD1a, CD3, CD4, CD8, myeloperoxidase, EG1, EG2, tryptase, interferon-gamma, interleukin (IL)-4, IL-5, IL-12, IL-13, receptors for CXC chemokines (CXCR) 3 and 4, and receptor 3 for CC chemokines.CD3+, CD4+ and CD8+ lymphocytes, and eosinophil and neutrophil granulocytes were significantly reduced in post-treatment tacrolimus specimens, while CD1a+ cells and mast cells were not. The expression of cytokines and chemokine receptors tested, except for CXCR3, was diminished by tacrolimus treatment. Moreover, tacrolimus produced a greater reduction of lymphocytes, eosinophils and most cytokines than that induced by hydrocortisone butyrate.Tacrolimus not only inhibits T-lymphocyte proliferation and cytokine production, but also plays an important role in the IL-12-induced shift from a T-helper (Th) 2 to a Th1 cytokine profile that characterizes the development of chronic AD. Tacrolimus also demonstrates wider pharmacodynamic effects than hydrocortisone.